Tools for Assessing the Protective Efficacy of TB Vaccines in Humans:


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2019
Historique:
received: 08 10 2019
accepted: 05 12 2019
entrez: 31 1 2020
pubmed: 31 1 2020
medline: 15 12 2020
Statut: epublish

Résumé

Tuberculosis (TB) remains a leading global cause of morbidity and mortality and an effective new vaccine is urgently needed. A major barrier to the rational development of novel TB vaccines is the lack of a validated immune correlate or biomarker of protection. Mycobacterial Growth Inhibition Assays (MGIAs) provide an unbiased measure of ability to control mycobacterial growth

Identifiants

pubmed: 31998295
doi: 10.3389/fimmu.2019.02983
pmc: PMC6968127
doi:

Substances chimiques

Interleukin-23 0
Tuberculosis Vaccines 0

Banques de données

ClinicalTrials.gov
['NCT01194180']
EudraCT
['EudraCT 010-018425-19']

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2983

Subventions

Organisme : Medical Research Council
ID : MR/R005850/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_17218
Pays : United Kingdom
Organisme : Wellcome Trust
ID : WT 206331/Z/17/Z
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 095780/Z/11/Z
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Department of Health
ID : IS-BRC-1215-20008
Pays : United Kingdom

Informations de copyright

Copyright © 2020 Tanner, Satti, Harris, O'Shea, Cizmeci, O'Connor, Chomka, Matsumiya, Wittenberg, Minassian, Meyer, Fletcher and McShane.

Références

Vaccine. 2015 Sep 29;33(40):5316-20
pubmed: 26256528
Clin Vaccine Immunol. 2009 Jul;16(7):1025-32
pubmed: 19458207
J Infect Dis. 2008 Aug 15;198(4):544-52
pubmed: 18582195
Hum Vaccin Immunother. 2012 Jun;8(6):706-14
pubmed: 22508415
Tuberculosis (Edinb). 2008 Nov;88(6):631-40
pubmed: 18801705
Tuberculosis (Edinb). 2014 Mar;94(2):105-10
pubmed: 24369986
Lancet. 1995 Nov 18;346(8986):1339-45
pubmed: 7475776
J Infect Dis. 2015 May 1;211(9):1499-509
pubmed: 25381367
Int J Epidemiol. 1993 Dec;22(6):1154-8
pubmed: 8144299
J Immunol Methods. 2019 Jun;469:1-10
pubmed: 30710562
Lancet. 2013 Mar 23;381(9871):1021-8
pubmed: 23391465
J Immunol. 2005 Nov 1;175(9):5765-73
pubmed: 16237068
Tuber Lung Dis. 1995 Jun;76(3):248-53
pubmed: 7548909
Gene. 2013 Feb 15;515(1):229-32
pubmed: 23219503
Cytokine. 2008 Feb;41(2):79-83
pubmed: 18218322
Sci Rep. 2018 Sep 27;8(1):14480
pubmed: 30262883
Cell. 2006 Feb 24;124(4):683-7
pubmed: 16497578
Front Immunol. 2017 Oct 05;8:1262
pubmed: 29051764
J Immunol. 1992 Jan 1;148(1):189-96
pubmed: 1727865
J Clin Invest. 2018 May 1;128(5):1837-1851
pubmed: 29461976
PLoS One. 2007 Sep 05;2(9):e853
pubmed: 17786224
Tuberculosis (Edinb). 2016 Dec;101:102-113
pubmed: 27865379
J Infect Dis. 2012 Apr 1;205(7):1035-42
pubmed: 22396610
Clin Vaccine Immunol. 2017 Sep 5;24(9):null
pubmed: 28701467
Tuberculosis (Edinb). 2013 Sep;93(5):551-7
pubmed: 23726784
Front Immunol. 2019 Jun 11;10:1317
pubmed: 31244856
Vaccine. 2016 Oct 17;34(44):5298-5305
pubmed: 27622301
Infect Immun. 2005 Sep;73(9):5782-8
pubmed: 16113296
Am J Respir Crit Care Med. 2010 Oct 15;182(8):1073-9
pubmed: 20558627
Semin Immunol. 2014 Dec;26(6):454-70
pubmed: 25453225
J Infect Dis. 1957 Sep-Oct;101(2):193-202
pubmed: 13475878
Sci Rep. 2017 Jun 6;7(1):2830
pubmed: 28588268
Clin Infect Dis. 2012 Jun;54(11):1615-7
pubmed: 22437237
Sci Rep. 2017 Mar 03;7:43478
pubmed: 28256545
Vaccine (Auckl). 2011 Oct;2011(1):3-13
pubmed: 24482781
BMC Med. 2016 May 16;14:76
pubmed: 27183822
Vaccine. 2009 Dec 11;28(2):317-22
pubmed: 19879231
J Infect Dis. 2001 Apr 15;183(8):1300-3
pubmed: 11262217
J Infect Dis. 2016 Mar 1;213(5):824-30
pubmed: 26450421
Eur Respir J. 1988 Jul;1(7):589-93
pubmed: 3181404
Clin Vaccine Immunol. 2013 Nov;20(11):1683-9
pubmed: 23986316
Microbes Infect. 2011 Nov;13(12-13):1099-110
pubmed: 21787878
Cell Physiol Biochem. 2017;41(4):1271-1284
pubmed: 28278498
J Immunol. 2008 Feb 1;180(3):1962-70
pubmed: 18209095
JCI Insight. 2019 Dec 5;4(23):null
pubmed: 31697647
Front Immunol. 2018 Dec 14;9:2893
pubmed: 30619265
Clin Sci (Lond). 2019 Jun 17;133(12):1271-1280
pubmed: 31209098
Clin Vaccine Immunol. 2014 Jul;21(7):1005-11
pubmed: 24828094
J Exp Med. 1993 Dec 1;178(6):2249-54
pubmed: 7504064
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Front Immunol. 2019 May 09;10:996
pubmed: 31143177
PLoS One. 2011;6(8):e23463
pubmed: 21887254
J Exp Med. 1993 Dec 1;178(6):2243-7
pubmed: 8245795
Am Rev Respir Dis. 1959 Aug;80:153-66
pubmed: 14430545
Vaccine. 2016 Sep 7;34(39):4656-4665
pubmed: 27527814
Proc Natl Acad Sci U S A. 2007 Jul 24;104(30):12434-9
pubmed: 17640915
J Infect Dis. 2002 Nov 15;186(10):1448-57
pubmed: 12404160
Trans R Soc Trop Med Hyg. 2005 May;99(5):363-8
pubmed: 15780343
J Infect Dis. 2014 Apr 15;209(8):1259-68
pubmed: 24273174
J Infect Dis. 2014 May 1;209(9):1354-61
pubmed: 24415790
Nat Med. 2004 Nov;10(11):1240-4
pubmed: 15502839
Nat Immunol. 2007 Apr;8(4):369-77
pubmed: 17351619
Infect Immun. 2004 Nov;72(11):6401-7
pubmed: 15501770
Nat Commun. 2016 May 06;7:11633
pubmed: 27151680
PLoS Pathog. 2015 May 22;11(5):e1004914
pubmed: 26001081
Acta Paediatr. 1953 Mar;42(2):113-25
pubmed: 13050390
J Immunol. 2008 Mar 1;180(5):3569-77
pubmed: 18292584

Auteurs

Rachel Tanner (R)

The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.

Iman Satti (I)

The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.

Stephanie A Harris (SA)

The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.

Matthew K O'Shea (MK)

The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
Institute of Microbiology and Infection, College of Medical and Dental Sciences, The University of Birmingham, Birmingham, United Kingdom.

Deniz Cizmeci (D)

The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.

Daniel O'Connor (D)

Department of Paediatrics, University of Oxford, Oxford, United Kingdom.

Agnieszka Chomka (A)

The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.

Magali Matsumiya (M)

The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.

Rachel Wittenberg (R)

The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.

Angela M Minassian (AM)

The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.

Joel Meyer (J)

The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.

Helen A Fletcher (HA)

The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
London School of Hygiene and Tropical Medicine, London, United Kingdom.

Helen McShane (H)

The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH